drug
revefenacin
Marketedupdated 3mo agoby Theravance Biopharma US Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying revefenacin
- phase4Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
- phase2Revefenacin in Acute Respiratory Insufficiency in COPD
- phase4Phase 4 COPD and Suboptimal Inspiratory Flow Rate
- phase3Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 31, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Oct 23, 2039method-of-use (U-2440)US 11484531
- Aug 29, 2039method-of-use (U-2440)US 12048692
- Aug 29, 2039method-of-use (U-2440)US 12285417
- Aug 25, 2031compositionUS 8541451
- Jul 14, 2030compositionUS 105500813.9y
- Jul 14, 2030method-of-use (U-2440)US 110082893.9y
- Jul 14, 2030formulationUS 116919483.9y
- Jul 14, 2030compositionUS 118588983.9y
- Jul 14, 2030compositionUS 97650283.9y
- Oct 31, 2028compositionUS 72886572.2y
News(1)
- Theravance, after clinical setbacks, agrees to $929M buyoutThe acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.biopharma_dive · 1mo ago
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that